Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Operating Leases (2018 - 2025)

Historic Operating Leases for Cytosorbents (CTSO) over the last 8 years, with Q3 2025 value amounting to $12.1 million.

  • Cytosorbents' Operating Leases fell 411.93% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 411.93%. This contributed to the annual value of $12.4 million for FY2024, which is 350.99% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Operating Leases is $12.1 million, which was down 411.93% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Operating Leases registered a high of $13.8 million during Q4 2021, and its lowest value of $923960.0 during Q1 2021.
  • Over the past 5 years, Cytosorbents' median Operating Leases value was $13.1 million (recorded in 2023), while the average stood at $12.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first surged by 137834.88% in 2022, then plummeted by 657.31% in 2025.
  • Quarter analysis of 5 years shows Cytosorbents' Operating Leases stood at $13.8 million in 2021, then fell by 4.13% to $13.3 million in 2022, then fell by 2.67% to $12.9 million in 2023, then decreased by 3.51% to $12.4 million in 2024, then fell by 3.16% to $12.1 million in 2025.
  • Its Operating Leases stands at $12.1 million for Q3 2025, versus $12.2 million for Q2 2025 and $12.3 million for Q1 2025.